Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1187 | TNBC | Basal A | Trametinib | MEK | MAPK | 16.7 | uM | 7812.036 | 1.0443 | 1.0877 | 1.0103 | |
| HCC1187 | TNBC | Basal A | Trametinib | MEK | MAPK | 0.0000427 | uM | 9244.012 | 1.1802 | 1.9421 | 0.4292 | |
| HCC1187 | TNBC | Basal A | Trametinib | MEK | MAPK | 0.000213 | uM | 9244.012 | 0.8796 | 0.4834 | 0.4292 | |
| HCC1187 | TNBC | Basal A | Trametinib | MEK | MAPK | 0.00107 | uM | 9244.012 | 1.1475 | 1.7555 | 0.4292 | |
| HCC1187 | TNBC | Basal A | Trametinib | MEK | MAPK | 0.00533 | uM | 9244.012 | 1.0477 | 1.2292 | 0.4292 | |
| HCC1187 | TNBC | Basal A | Trametinib | MEK | MAPK | 0.0267 | uM | 9244.012 | 1.0747 | 1.3654 | 0.4292 | |
| HCC1187 | TNBC | Basal A | Trametinib | MEK | MAPK | 0.133 | uM | 9244.012 | 1.0589 | 1.2853 | 0.4292 | |
| HCC1187 | TNBC | Basal A | Trametinib | MEK | MAPK | 0.667 | uM | 9244.012 | 1.0896 | 1.4426 | 0.4292 | |
| HCC1187 | TNBC | Basal A | Trametinib | MEK | MAPK | 3.33 | uM | 9244.012 | 1.1010 | 1.5028 | 0.4292 | |
| HCC1187 | TNBC | Basal A | Trametinib | MEK | MAPK | 16.7 | uM | 9244.012 | 0.9569 | 0.8051 | 0.4292 | |
| HCC1395 | TNBC | Basal B | Trametinib | MEK | MAPK | 0.0000427 | uM | 7813.012 | 0.9907 | 0.9822 | 1.0493 | |
| HCC1395 | TNBC | Basal B | Trametinib | MEK | MAPK | 0.000213 | uM | 7813.012 | 0.7083 | 0.4397 | 1.0493 | |
| HCC1395 | TNBC | Basal B | Trametinib | MEK | MAPK | 0.00107 | uM | 7813.012 | 0.8673 | 0.7462 | 1.0493 | |
| HCC1395 | TNBC | Basal B | Trametinib | MEK | MAPK | 0.00533 | uM | 7813.012 | 0.9813 | 0.9643 | 1.0493 | |
| HCC1395 | TNBC | Basal B | Trametinib | MEK | MAPK | 0.0267 | uM | 7813.012 | 0.9357 | 0.8772 | 1.0493 | |
| HCC1395 | TNBC | Basal B | Trametinib | MEK | MAPK | 0.133 | uM | 7813.012 | 0.8679 | 0.7474 | 1.0493 | |
| HCC1395 | TNBC | Basal B | Trametinib | MEK | MAPK | 0.667 | uM | 7813.012 | 0.5615 | 0.1540 | 1.0493 | |
| HCC1395 | TNBC | Basal B | Trametinib | MEK | MAPK | 3.33 | uM | 7813.012 | 0.7276 | 0.4771 | 1.0493 | |
| HCC1395 | TNBC | Basal B | Trametinib | MEK | MAPK | 16.7 | uM | 7813.012 | 0.6510 | 0.3285 | 1.0493 | |
| HCC1395 | TNBC | Basal B | Trametinib | MEK | MAPK | 0.0000427 | uM | 7813.036 | 1.0527 | 1.1321 | 0.8030 | |
| HCC1395 | TNBC | Basal B | Trametinib | MEK | MAPK | 0.000213 | uM | 7813.036 | 1.0166 | 1.0415 | 0.8030 | |
| HCC1395 | TNBC | Basal B | Trametinib | MEK | MAPK | 0.00107 | uM | 7813.036 | 0.9542 | 0.8867 | 0.8030 | |
| HCC1395 | TNBC | Basal B | Trametinib | MEK | MAPK | 0.00533 | uM | 7813.036 | 0.9972 | 0.9931 | 0.8030 | |
| HCC1395 | TNBC | Basal B | Trametinib | MEK | MAPK | 0.0267 | uM | 7813.036 | 0.9847 | 0.9621 | 0.8030 | |
| HCC1395 | TNBC | Basal B | Trametinib | MEK | MAPK | 0.133 | uM | 7813.036 | 0.8717 | 0.6857 | 0.8030 |